Physician profile
David Morris
NPI 1952367393
$13,399.24
in general payments reported to CMS, 2019-2025
42 companies · $1,624 in 2025
The $1,624 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,665 · 2020: $1,597 · 2021: $2,306 · 2022: $1,901 · 2023: $1,781 · 2024: $2,525 · 2025: $1,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,905 · Education: $25.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,905.38 |
| Education | $25.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,440.80 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,769.01 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Takeda Pharmaceuticals U.S.A., INC. | $1,466.56 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $1,398.60 | 2019-2025 | Livdelzi |
| Janssen Biotech, INC. | $1,157.37 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $556.10 | 2019-2025 | |
| Qol Medical, LLC | $338.42 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $337.51 | 2019-2024 | Linzess |
| Celgene Corporation | $329.96 | 2021-2024 | Zeposia |
| Genzyme Corporation | $304.38 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $299.93 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $255.78 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $198.81 | 2020-2024 | Rebyota |
| Lilly USA, LLC | $131.27 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $128.18 | 2021-2023 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $124.74 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $120.07 | 2020 | |
| Aimmune Therapeutics, INC. | $103.35 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $102.13 | 2019-2024 | Dificid |
| Redhill Biopharma INC. | $88.45 | 2020-2021 | |
| Madrigal Pharmaceuticals | $73.79 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $65.83 | 2024-2025 | Iqirvo |
| Amgen INC. | $64.38 | 2022-2023 | Amjevita, Avsola |
| Ucb, INC. | $60.15 | 2019-2020 | |
| Daiichi Sankyo INC. | $54.36 | 2020 | |
| Celltrion USA INC. | $50.18 | 2023-2025 | Zymfentra, Yuflyma, Vegzelma |
| Braintree Laboratories, INC. | $45.09 | 2020-2021 | |
| Medtronic, INC. | $44.57 | 2024-2025 | Interstim |
| Phathom Pharmaceuticals, INC. | $40.54 | 2024-2025 | Voquezna |
| Biocon Biologics INC | $38.43 | 2025 | Yesintek |
| Amag Pharmaceuticals, INC. | $36.37 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.47 | 2023 | Zeposia |
| Eton Pharmaceuticals, INC. | $24.72 | 2025 | Carglumic Acid, Betaine Anhydrous, Nitisinone |
| Ethicon US, LLC | $20.29 | 2019 | |
| Mylan Institutional INC. | $19.30 | 2023 | |
| Boston Scientific Corporation | $15.80 | 2019 | |
| Portola Pharmaceuticals, LLC | $15.02 | 2019 | |
| Ardelyx, INC. | $14.34 | 2023 | Ibsrela |
| Fresenius Kabi USA, LLC | $13.94 | 2023 | |
| Endo Pharmaceuticals INC. | $12.16 | 2019 | |
| Baudax Bio INC. | $12.09 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.